MGMT and neoplasm: As for other tumor types, prior preclinical evidence showed that MGMT‐silencing, spontaneously or via O(6)‐benzyl guanine, results in PAC growth inhibition and increased sensitivity to gemcitabine and to alkylating agents, including temozolomide [37, 38, 39].